首页 > 最新文献

Haematologica最新文献

英文 中文
Late-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib. 一名接受吉妥珠单抗奥佐米星和格拉斯替吉治疗的 MYC 扩增复发/难治性急性髓性白血病患者的晚期 NPM1 突变。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2023.284922
Sonia Jaramillo, Michael Scherer, Chelsea Szu-Tu, Sergi Beneyto-Calabuig, Carsten Müller-Tidow, Richard F Schlenk, Michael Hundemer, Lars Velten, Caroline Pabst
{"title":"Late-onset <i>NPM1</i> mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib.","authors":"Sonia Jaramillo, Michael Scherer, Chelsea Szu-Tu, Sergi Beneyto-Calabuig, Carsten Müller-Tidow, Richard F Schlenk, Michael Hundemer, Lars Velten, Caroline Pabst","doi":"10.3324/haematol.2023.284922","DOIUrl":"10.3324/haematol.2023.284922","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to: Stem cell factor and erythropoietin-independent production of cultured reticulocytes. 勘误:干细胞因子和红细胞生成素对培养网织红细胞的依赖性。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2024.286256
Emmanuel Olivier, Shouping Zhang, Zi Yan, Eric E Bouhassira
{"title":"<i>Erratum</i> to: Stem cell factor and erythropoietin-independent production of cultured reticulocytes.","authors":"Emmanuel Olivier, Shouping Zhang, Zi Yan, Eric E Bouhassira","doi":"10.3324/haematol.2024.286256","DOIUrl":"10.3324/haematol.2024.286256","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of autoimmune diseases in patients with sickle cell disease: a single center retrospective analysis. 镰状细胞病患者自身免疫性疾病的患病率:单中心回顾性分析。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2023.284552
Man Wai Tang, Erfan Nur, Charlotte F J Van Tuijn, Bart J Biemond
{"title":"Prevalence of autoimmune diseases in patients with sickle cell disease: a single center retrospective analysis.","authors":"Man Wai Tang, Erfan Nur, Charlotte F J Van Tuijn, Bart J Biemond","doi":"10.3324/haematol.2023.284552","DOIUrl":"10.3324/haematol.2023.284552","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HES6: an emerging player in human hematopoiesis. HES6:人类造血过程中的新角色。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2024.285426
Jian Xu, Wei Du
{"title":"HES6: an emerging player in human hematopoiesis.","authors":"Jian Xu, Wei Du","doi":"10.3324/haematol.2024.285426","DOIUrl":"10.3324/haematol.2024.285426","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes of newly diagnosed POEMS syndrome patients who received first-line lenalidomide-based therapy. 接受来那度胺一线治疗的新确诊 POEMS 综合征患者的长期疗效。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2024.285282
Xue-Min Gao, An-An Li, Hao Zhao, Kai-Ni Shen, Jian Li
{"title":"Long-term outcomes of newly diagnosed POEMS syndrome patients who received first-line lenalidomide-based therapy.","authors":"Xue-Min Gao, An-An Li, Hao Zhao, Kai-Ni Shen, Jian Li","doi":"10.3324/haematol.2024.285282","DOIUrl":"10.3324/haematol.2024.285282","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
No clear benefit of preventive cranial radiotherapy in childhood Philadelphia-positive acute lymphoblastic leukemia: a retrospective analysis of the EsPhALL2010 study. 儿童费城阳性急性淋巴细胞白血病预防性颅脑放疗无明显疗效:EsPhALL2010 研究的回顾性分析。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2024.285253
Valentino Conter, Maria Grazia Valsecchi, Paola De Lorenzo, Virginie Gandemer, Mats Heyman, Vaskar Saha, Paulina Diaz, Chi-Kong Li, Andishe Attarbaschi, Gabriele Escherich, Jan Stary, Martin Schrappe, Rob Pieters, Gunnar Cario, Andrea Biondi
{"title":"No clear benefit of preventive cranial radiotherapy in childhood Philadelphia-positive acute lymphoblastic leukemia: a retrospective analysis of the EsPhALL2010 study.","authors":"Valentino Conter, Maria Grazia Valsecchi, Paola De Lorenzo, Virginie Gandemer, Mats Heyman, Vaskar Saha, Paulina Diaz, Chi-Kong Li, Andishe Attarbaschi, Gabriele Escherich, Jan Stary, Martin Schrappe, Rob Pieters, Gunnar Cario, Andrea Biondi","doi":"10.3324/haematol.2024.285253","DOIUrl":"10.3324/haematol.2024.285253","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma. 勘误:泪液中的可溶性 B 细胞成熟抗原是多发性骨髓瘤角膜病的潜在生物标志物和介质。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2024.285821
Umair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K Martin Kortüm, Johannes M Waldschmidt
{"title":"<i>Erratum</i> to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.","authors":"Umair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K Martin Kortüm, Johannes M Waldschmidt","doi":"10.3324/haematol.2024.285821","DOIUrl":"10.3324/haematol.2024.285821","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aspirin is a life-saving drug for patients with acute myocardial infarction. 阿司匹林是急性心肌梗死患者的救命药。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2024.286215
Marco Cattaneo
{"title":"Aspirin is a life-saving drug for patients with acute myocardial infarction.","authors":"Marco Cattaneo","doi":"10.3324/haematol.2024.286215","DOIUrl":"10.3324/haematol.2024.286215","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma. 基因改变对原发性玻璃体视网膜淋巴瘤中枢神经系统进展的影响。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2023.284953
Kota Yoshifuji, Daichi Sadato, Takashi Toya, Yotaro Motomura, Chizuko Hirama, Hiroshi Takase, Kouhei Yamamoto, Yuka Harada, Takehiko Mori, Toshikage Nagao

Primary vitreoretinal lymphoma (PVRL) is a rare malignant lymphoma subtype with an unfavorable prognosis due to frequent central nervous system (CNS) progression. Thus, identifying factors associated with CNS progression is essential for improving the prognosis of PVRL patients. Accordingly, we conducted a comprehensive genetic analysis using archived vitreous humor samples of 36 PVRL patients diagnosed and treated at our institution and retrospectively examined the relationship between genetic alterations and CNS progression. Whole-exome sequencing (N=2) and amplicon sequencing using a custom panel of 107 lymphomagenesis-related genes (N=34) were performed to assess mutations and copy number alterations. The median number of pathogenic genetic alterations per case was 12 (range, 0-22). Pathogenic genetic alterations of CDKN2A, MYD88, CDKN2B, PRDM1, PIM1, ETV6, CD79B, and IGLL5, as well as aberrant somatic hypermutations, were frequently detected. The frequency of ETV6 loss and PRDM1 alteration (mutation and loss) was 23% and 49%, respectively. Multivariate analysis revealed ETV6 loss (hazard ratio [HR]=3.26, 95% confidence interval [CI]: 1.08-9.85) and PRDM1 alteration (HR=2.52, 95% CI: 1.03-6.16) as candidate risk factors associated with CNS progression of PVRL. Moreover, these two genetic factors defined slow-, intermediate-, and rapid-progression groups (0, 1, and 2 factors, respectively), and the median period to CNS progression differed significantly among them (52 vs. 33 vs. 20 months, respectively). Our findings suggest that genetic factors predict the CNS progression of PVRL effectively, and the genetics-based CNS progression model might lead to stratification of treatment.

原发性玻璃体视网膜淋巴瘤(PVRL)是一种罕见的恶性淋巴瘤亚型,由于常发生中枢神经系统(CNS)进展,预后较差。因此,确定与中枢神经系统进展相关的因素对于改善 PVRL 患者的预后至关重要。因此,我们利用本院诊断和治疗的 36 例 PVRL 患者的玻璃体样本进行了全面的基因分析,并回顾性地研究了基因改变与中枢神经系统进展之间的关系。为评估基因突变和拷贝数改变,我们进行了全外显子组测序(n = 2)和扩增子测序(n = 34),使用的是107个淋巴瘤发生相关基因的定制面板。每个病例致病基因改变的中位数为 12 个(范围:0- 22)。CDKN2A、MYD88、CDKN2B、PRDM1、PIM1、ETV6、CD79B 和 IGLL5 的致病基因改变以及异常体细胞高突变经常被检测到。ETV6缺失和PRDM1改变(突变和缺失)的频率分别为23%和49%。多变量分析显示,ETV6缺失(危险比[HR]:3.26,95%置信区间[CI]:1.08-9.85)和PRDM1改变(HR:2.52,95%置信区间[CI]:1.03-6.16)是与PVRL中枢神经系统进展相关的候选危险因素。此外,这两个遗传因素定义了缓慢进展组、中等进展组和快速进展组(分别为 0、1 和 2 个因素),它们之间的中位中枢神经系统进展期存在显著差异(分别为 52 个月 vs. 33 个月 vs. 20 个月)。我们的研究结果表明,遗传因素能有效预测PVRL的中枢神经系统进展,基于遗传学的中枢神经系统进展模型可能有助于分层治疗。
{"title":"Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma.","authors":"Kota Yoshifuji, Daichi Sadato, Takashi Toya, Yotaro Motomura, Chizuko Hirama, Hiroshi Takase, Kouhei Yamamoto, Yuka Harada, Takehiko Mori, Toshikage Nagao","doi":"10.3324/haematol.2023.284953","DOIUrl":"10.3324/haematol.2023.284953","url":null,"abstract":"<p><p>Primary vitreoretinal lymphoma (PVRL) is a rare malignant lymphoma subtype with an unfavorable prognosis due to frequent central nervous system (CNS) progression. Thus, identifying factors associated with CNS progression is essential for improving the prognosis of PVRL patients. Accordingly, we conducted a comprehensive genetic analysis using archived vitreous humor samples of 36 PVRL patients diagnosed and treated at our institution and retrospectively examined the relationship between genetic alterations and CNS progression. Whole-exome sequencing (N=2) and amplicon sequencing using a custom panel of 107 lymphomagenesis-related genes (N=34) were performed to assess mutations and copy number alterations. The median number of pathogenic genetic alterations per case was 12 (range, 0-22). Pathogenic genetic alterations of CDKN2A, MYD88, CDKN2B, PRDM1, PIM1, ETV6, CD79B, and IGLL5, as well as aberrant somatic hypermutations, were frequently detected. The frequency of ETV6 loss and PRDM1 alteration (mutation and loss) was 23% and 49%, respectively. Multivariate analysis revealed ETV6 loss (hazard ratio [HR]=3.26, 95% confidence interval [CI]: 1.08-9.85) and PRDM1 alteration (HR=2.52, 95% CI: 1.03-6.16) as candidate risk factors associated with CNS progression of PVRL. Moreover, these two genetic factors defined slow-, intermediate-, and rapid-progression groups (0, 1, and 2 factors, respectively), and the median period to CNS progression differed significantly among them (52 vs. 33 vs. 20 months, respectively). Our findings suggest that genetic factors predict the CNS progression of PVRL effectively, and the genetics-based CNS progression model might lead to stratification of treatment.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute myeloid leukemia at first relapse: approaching the precipice. 急性髓性白血病首次复发:逼近悬崖。
IF 8.2 1区 医学 Q1 HEMATOLOGY Pub Date : 2024-11-01 DOI: 10.3324/haematol.2024.285676
Xavier Calvo
{"title":"Acute myeloid leukemia at first relapse: approaching the precipice.","authors":"Xavier Calvo","doi":"10.3324/haematol.2024.285676","DOIUrl":"10.3324/haematol.2024.285676","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":null,"pages":null},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Haematologica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1